Health Care Equipment

Pre-open movers US stock futures are higher this morning, as investors are awaiting economic data. Futures for the Dow Jones Industrial Average surged 13 points to 13,143.00 and S&P 500 index futures rose 2 points to 1,390.70. Nasdaq 100 futures gained 5.25 points to 2,708.00. A Peek Into...

M/A-COM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at $19.00 per share. A total of 5,556,000 shares are being offered by M/A-COM Tech and 444,000 shares are being offered by a selling stockholder...

Shares of MAKO Surgical (NASDAQ: MAKO) are seeing much strength during Wednesday's trading session after the company reported fourth quarter and yearly results yesterday, which were better than analysts' expectations. MAKO Surgical reported fourth-quarter EPS of $-0.14 versus the estimated $-0.14...

Piper Jaffray increases its price target on Overweight-rated MAKO Surgical Corp (NASDAQ: MAKO) to $50, up $13, reflecting potential catalysts and fundamentals that should provide support to the company. Piper Jaffray says, "WE see potential positive catalysts including the potential approval of...

According to a research report published today, Canaccord has lowered LeMaitre Vascular's (NASDAQ: LMAT) PT to $7.50 following lower-than-expected 4Q results. Canaccord commented in the report, “Q4 results were disappointing with both revenue and operating income much lower than expected. 2012...

GE Healthcare (NYSE: GE) and Masimo (NASDAQ: MASI) jointly announced a long-term agreement under which GE will incorporate Masimo rainbow® SET technology into many of GE Healthcare's patient monitoring products.

Feltl & Company maintains its Hold rating on Masimo Corporation (NASDAQ: MASI) following largely in-line Q4 reported by the company. Price target of $23.50 is reiterated. Feltl & Company notes, "Masimo beat our revenue estimates in every category, EPS was inline with our estimates and...

According to a research report published today by Collins Stewart, Masimo Corporation's (NASDAQ: MASI) 4Q11 results provided initial 2012 guidance that were in line with consensus. In the report, Masimo explained further, “Following a couple quarters of downward revisions, we view this as a...

In a research report published earlier today, Bank of America noted that Masimo Corporation's (NASDAQ: MASI) Q4 results and 2012 guidance are in-line, but data points are mixed. “Last night MASI reported Q4 results that were relatively in-line with consensus and with the revised guidance provided...

Brean Murray Carret raises its price target on Buy-rated Masimo Corporation (NASDAQ: MASI) a highly encouraging guidance update following an inline Q4. Brean Murray Carret says, "Guidance for 2012 was solid, in our view, and management's detailed commentary should 1) increase confidence that...

According to a research report published earlier today by Brean Murray Carret, Masimo Corporation (NASDAQ: MASI) is scheduled to report Q4:11 results this evening after close. In the report, Brean Murray Carret commented, “As we had highlighted in our 1/13 update, a careful dig through our model...

Author: Eric Steiman Covestor model: Undervalued Opportunities The Undervalued Opportunities model outpaced the S&P 500 and the Dow Jones Global by over 1500 basis points each in January. A few reasons were the fund's holdings in Mako Surgical (MAKO) and Renren (RENN), both of which...

Author: Bob Freedland Covestor model: Healthcare The Healthcare Model had a relatively flat month in January, as this group of stocks underperformed the S&P 500. I continue to work to identify the strongest collection of stocks in this evolving area of medical care and related industries....

Citigroup lowers its rating on Masimo Corporation (NASDAQ: MASI) to Sell from Neutral and lowers its price target to $20 from $21 on utilization challenges. Citigroup says, "2012 is unlikely to get easier for MASI after a tough 2011 where we saw further margin erosion and limited technology...

Goldman Sachs reiterates its Buy rating on MAKO Surgical (NASDAQ: MAKO) and raises its price target to $38 from $36 on higher estimates following fourth quarter pre-announcement from the company. Goldman Sachs notes, "4Q results should allay concerns regarding average selling prices (ASPs) in...